EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study

Daniel R Morales iD, Fan Bu, Benjamin Viernes, Scott L DuVall, Michael E Matheny, Katherine R Simon, Thomas Falconer, Lauren R Richter, Anna Ostropolets, Wallis C Y Lau, Kenneth K C Man, Shounak Chattopadhyay und 19 weitere

Diabetes Care · 2025

DOI: 10.2337/dc25-0154 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes Care, 2025. Verfasst von Daniel R Morales und 30 weiteren Autor:innen. Beteiligte Einrichtung: Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, U.K. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NLM NIH HHS, NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To assess the association between glucagon-like peptide 1 receptor agonist (GLP-1RA) use and risk of incident thyroid tumors. RESEARCH DESIGN AND METHODS The retrospective, active-comparator new-user cohort study used international administrative claims and electronic health record databases. Participants included patients with type 2 diabetes mellitus (T2DM) with prior metformin therapy initiating a GLP-1RA versus new users of sodium–glucose cotransporter 2 inhibitors (SGLT2is), dipeptidyl peptidase 4 inhibitors (DPP-4is), and sulfonylureas (SUs). The outcome was incident thyroid tumor and thyroid malignancy. Propensity score matching and stratification were used to adjust for confounders with an intention-to-treat and on-treatment strategy. Cox regression was used to estimate hazard ratios (HRs) pooled using a random-effects meta-analysis. Unmeasured confounding was evaluated using negative outcomes, with calibration of the HR. RESULTS A total of 460,032 users of GLP-1RAs, 717,792 users of SGLT2is, 2,055,583 users of DPP-4is, and 1,119,868 users of SUs were included. Only U.S. cohorts passed study diagnostics. Thyroid tumor incidence ranged from 0.88 to 1.03 per 1,000 person-years in GLP-1RA cohorts. GLP-1RA exposure was not associated with an increased risk of thyroid tumors compared with SGLT2is, DPP-4is, or SUs (meta-analysis: GLP-1RA vs. SGLT2i HR range from 0.83 [95% CI 0.57–1.27] to 0.95 [0.85–1.06]; GLP-1RA vs. SU HR range from 0.95 [0.75–1.20] to 1.03 [0.87–1.23]; GLP-1RA vs. DPP-4i HR range from 0.78 [0.60–1.01] to 0.93 [0.83–1.04]). Analysis using thyroid malignancy and including a 1-year lag period produced similar conclusions. CONCLUSIONS In patients with T2DM initiating second-line treatments, we observed no increased risk of thyroid tumors with GLP-1RA exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansFemaleRetrospective StudiesMaleMiddle AgedAgedDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 Inhibitors

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, U.K.
  • Department of Biostatistics, University of Michigan at Ann Arbor, Ann Arbor, MI.
  • Veterans Affairs Informatics and Computing Infrastructure Department of Veterans Affairs, Salt Lake City, UT.
  • Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT.
  • Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, TN.
  • Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN.

ORCID-Profile: Daniel R Morales, Nestoras Mathioudakis, Feng Sun, Carlen Reyes, Rohan Khera

Förderung

  • NIH HHS
  • NLM NIH HHS
  • NHGRI NIH HHS
  • NHLBI NIH HHS
  • US Department of Veterans Affairs
  • National Institutes of Health

Zitieren

APA

Morales, D. R., Bu, F., Viernes, B., DuVall, S. L., Matheny, M. E., Simon, K. R., Falconer, T., Richter, L. R., Ostropolets, A., Lau, W. C. Y., Man, K. K. C., Chattopadhyay, S., Mathioudakis, N., Minty, E., Nishimura, A., Sun, F., Yin, C., Seager, S. L., Chai, Y., …, & Suchard, M. A. (2025). Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care. https://doi.org/10.2337/dc25-0154

Vancouver

Morales DR, Bu F, Viernes B, DuVall SL, Matheny ME, Simon KR, et al. Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care. 2025. doi:10.2337/dc25-0154

BibTeX
@article{Morales2025,
  author = {Morales, Daniel R and Bu, Fan and Viernes, Benjamin and DuVall, Scott L and Matheny, Michael E and Simon, Katherine R and Falconer, Thomas and Richter, Lauren R and Ostropolets, Anna and Lau, Wallis C Y and Man, Kenneth K C and Chattopadhyay, Shounak and Mathioudakis, Nestoras and Minty, Evan and Nishimura, Akihiko and Sun, Feng and Yin, Can and Seager, Sarah L and Chai, Yi and Zhou, Jin J and Lu, Yuan and Reyes, Carlen and Pistillo, Andrea and Duarte-Salles, Talita and Blacketer, Clair and Schuemie, Martijn J and Ryan, Patrick B and Krumholz, Harlan M and Hripcsak, George and Khera, Rohan and Suchard, Marc A},
  title = {Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study},
  journal = {Diabetes Care},
  year = {2025},
  doi = {10.2337/dc25-0154}
}
Kostenlos starten →